Scholarlink

<p>The targeting of G protein-coupled receptors (GPCRs) has emerged as a promising strategy for developing novel cancer therapies. Moreover, inactivation of the Hippo signaling pathway is recognized as a critical driver of gastric cancer (GC) progression. However, the precise molecular mechanisms underlying cross-talk between GPCRs and the Hippo pathway remain to be further investigated. Here, we identify NPSR1 as an oncogenic driver promoting GC advancement. NPSR1 is significantly overexpressed in GC tissues and negatively correlates with patient prognosis. Both in vivo and in vitro studies demonstrated that NPSR1 overexpression robustly accelerated GC cell proliferation and migration, while its silencing suppressed tumor progression. Mechanistically, our findings revealed a dual regulatory axis: (i) NPSR1 activated the cAMP/CREB pathway to enhance YAP1 transcription; and (ii) it directly facilitated phosphatase PP2Ac expression, thereby reducing YAP1 phosphorylation. This promotes the translocation of YAP1 from the cytoplasm to the nucleus, enhancing its oncogenic function. Our study uncovers a novel molecular link between NPSR1 hyperactivation and Hippo pathway suppression through coordinated transcriptional upregulation and post-translational modulation of YAP1. These results highlight NPSR1 as a potential therapeutic target for GC, offering a rationale for developing targeted inhibitors to restore Hippo signaling.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting NPSR1-mediated Hippo-YAP1 dysregulation suppresses gastric cancer progression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Wenjing Qin,
  • Mei Ma,
  • Weidan Fang,
  • Xian Wang,
  • Bin Yu

摘要

The targeting of G protein-coupled receptors (GPCRs) has emerged as a promising strategy for developing novel cancer therapies. Moreover, inactivation of the Hippo signaling pathway is recognized as a critical driver of gastric cancer (GC) progression. However, the precise molecular mechanisms underlying cross-talk between GPCRs and the Hippo pathway remain to be further investigated. Here, we identify NPSR1 as an oncogenic driver promoting GC advancement. NPSR1 is significantly overexpressed in GC tissues and negatively correlates with patient prognosis. Both in vivo and in vitro studies demonstrated that NPSR1 overexpression robustly accelerated GC cell proliferation and migration, while its silencing suppressed tumor progression. Mechanistically, our findings revealed a dual regulatory axis: (i) NPSR1 activated the cAMP/CREB pathway to enhance YAP1 transcription; and (ii) it directly facilitated phosphatase PP2Ac expression, thereby reducing YAP1 phosphorylation. This promotes the translocation of YAP1 from the cytoplasm to the nucleus, enhancing its oncogenic function. Our study uncovers a novel molecular link between NPSR1 hyperactivation and Hippo pathway suppression through coordinated transcriptional upregulation and post-translational modulation of YAP1. These results highlight NPSR1 as a potential therapeutic target for GC, offering a rationale for developing targeted inhibitors to restore Hippo signaling.